乾癬治療薬市場：分子、投与経路、剤形、作用機序別-2025-2030年の世界予測

乾癬治療薬市場は、2023年に216億2,000万米ドルと評価され、2024年には237億1,000万米ドルに達すると予測され、CAGR 9.77％で成長し、2030年には415億5,000万米ドルに達すると予測されています。

乾癬治療薬市場には、赤くうろこ状の斑点を特徴とする慢性の自己免疫性皮膚疾患である乾癬の症状を緩和するためにデザインされた様々な治療法が含まれます。炎症と皮膚細胞増殖の管理に重点を置き、治療の選択肢には外用剤、光線療法、特定の免疫経路を標的とする生物学的製剤のような全身投与薬が含まれます。乾癬治療薬を進める必要性は、この病気が患者のQOLに与える影響と、従来の治療法の有効性と安全性が限られていることに起因しています。これらの治療薬は、病院、専門クリニック、在宅医療など多様な場面で応用され、医療関連の質の向上と経済的負担の懸念の両方に対処しています。市場の拡大は、乾癬の有病率の増加、認知度の向上、バイオテクノロジーの進歩によって推進されています。主な影響要因としては、効率的な治療に対する患者の需要の高まり、新薬の承認、生物製剤や低分子の技術進歩などが挙げられます。注目すべき機会のひとつは個別化医療、特にオーダーメイドの生物製剤の開発であり、より効果的な患者の転帰を促進します。市場のプレーヤーはまた、低分子阻害剤や遺伝子治療などの新しい治療分野を模索しており、これらは大きな成長の可能性を示しています。

逆に、高い治療費、厳しい規制プロセス、特定の治療法の長期使用に伴う副作用などの課題が成長を妨げています。患者の服薬アドヒアランスは、乾癬の慢性的な性質により、市場の状況をさらに複雑にする可能性があります。革新的な治療法は、有効性と安全性を向上させた新規の生物学的製剤の調査、遠隔患者管理のための遠隔医療、患者層別化と治療レジメンの改善のためのAIの活用にあります。市場はダイナミックで受容的な性質を示すが、持続的成長には研究への継続的投資と課題克服が不可欠です。企業は、戦略的パートナーシップを優先し、パイプライン製品を拡大し、新たな市場機会を捉えるために包括的なデジタルマーケティングキャンペーンに取り組むことが推奨されます。

市場力学：急速に進化する乾癬治療薬市場における主要市場インサイトの解明

乾癬治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の高齢者人口の増加
  • 尋常性乾癬および関節症性乾癬の罹患率の増加
  • このような治療薬に対する有利な償還政策
• 市場抑制要因
  • 治療薬の高コスト
• 市場機会
  • 生物学的製剤の処方量および承認の増加
  • 新たな生物製剤や新規パイプライン医薬品の開発
• 市場の課題
  • 投薬による健康リスクの可能性

ポーターの5つの力：乾癬治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：乾癬治療薬市場における外部からの影響の把握

外部マクロ環境要因は、乾癬治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析乾癬治療薬市場における競合情勢の把握

乾癬治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス乾癬治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、乾癬治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨乾癬治療薬市場における成功への道筋を描く

乾癬治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大の可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で高齢者人口が増加
    • 尋常性乾癬および乾癬性関節炎の発生率の増加
    • このような治療薬に対する有利な償還政策
  • 抑制要因
    • 治療費の高騰
  • 機会
    • 生物学的製剤の処方量と承認数の増加
    • 新しい生物製剤と新規パイプライン医薬品の新たな開発
  • 課題
    • 薬による健康リスクの可能性
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 乾癬治療薬市場分子別

• 生物学的製剤
• 小分子

第7章 乾癬治療薬市場：投与経路別

• オーラル
• 非経口
• 話題

第8章 乾癬治療薬市場剤形別

• 液体
• 半固体
• 固体

第9章 乾癬治療薬市場作用機序別

• ILブロッカー
• PDE4阻害剤
• TNF阻害剤

第10章 南北アメリカの乾癬治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の乾癬治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの乾癬治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Amgen, Inc.
• Astellas Pharma Inc.
• AstraZeneca Plc
• Bausch Health Companies Inc.
• Boehringer Ingelheim International GmbH
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• GlaxoSmithKline plc
• Johnson & Johnson services, inc
• LEO Pharma A/S
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc
• Sun Pharmaceutical Industries Limited

LIST OF FIGURES

• FIGURE 1. PSORIASIS THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. PSORIASIS THERAPEUTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. PSORIASIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. PSORIASIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PSORIASIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. PSORIASIS THERAPEUTICS MARKET DYNAMICS
• TABLE 7. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY LIQUID, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SEMI-SOLID, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SOLID, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL BLOCKER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PDE4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 35. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 36. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 37. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 38. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 57. CHINA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 58. CHINA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 59. CHINA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 60. CHINA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 61. INDIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 62. INDIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 63. INDIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 64. INDIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 65. INDONESIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 69. JAPAN PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 73. MALAYSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 77. PHILIPPINES PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 81. SINGAPORE PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 89. TAIWAN PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 93. THAILAND PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 97. VIETNAM PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 106. DENMARK PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 110. EGYPT PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 114. FINLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 118. FRANCE PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 122. GERMANY PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 126. ISRAEL PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 130. ITALY PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 131. ITALY PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 132. ITALY PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 133. ITALY PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 134. NETHERLANDS PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 138. NIGERIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 142. NORWAY PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 146. POLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 147. POLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 148. POLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 149. POLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 150. QATAR PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 151. QATAR PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 152. QATAR PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 153. QATAR PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 154. RUSSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 158. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 162. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 166. SPAIN PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 170. SWEDEN PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 174. SWITZERLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 178. TURKEY PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 182. UNITED ARAB EMIRATES PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 186. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 190. PSORIASIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 191. PSORIASIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Psoriasis Therapeutics Market was valued at USD 21.62 billion in 2023, expected to reach USD 23.71 billion in 2024, and is projected to grow at a CAGR of 9.77%, to USD 41.55 billion by 2030.

The psoriasis therapeutics market encompasses a range of medical treatments designed to alleviate the symptoms of psoriasis, a chronic autoimmune skin disease characterized by red, scaly patches. With a focus on managing inflammation and skin cell proliferation, treatment options include topical agents, phototherapy, and systemic medications like biologics targeting specific immune pathways. The necessity of advancing psoriasis therapeutics stems from the disease's impact on patients' quality of life and the limited efficacy and safety of traditional treatments. These therapeutics are applied across diverse settings, including hospitals, specialty clinics, and home care, addressing both health-related quality improvement and economic burden concerns. The market's expansion is propelled by an increasing prevalence of psoriasis, growing awareness, and advancements in biotechnology. Key influencing factors include rising patient demand for efficient treatments, new drug approvals, and technological advancements in biologics and small molecules. One notable opportunity lies in personalized medicine, particularly the development of tailor-made biologics, fostering more effective patient outcomes. Market players are also exploring new therapy areas, such as small-molecule inhibitors and gene therapies, which underline significant growth potential.

Conversely, growth is hampered by challenges such as high treatment costs, stringent regulatory processes, and side-effects associated with long-term use of certain therapies. Patient adherence may further complicate the market landscape due to the chronic nature of psoriasis. Innovation lies in researching novel biologic agents with enhanced efficacy and safety profiles, exploring telemedicine for remote patient management, and leveraging AI for improved patient stratification and treatment regimens. The market shows a dynamic and receptive nature, yet continuous investment in research and overcoming these challenges will be vital for sustained growth. Businesses are recommended to prioritize strategic partnerships, expand pipeline products, and engage in comprehensive digital marketing campaigns to capture emerging market opportunities.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Psoriasis Therapeutics Market

The Psoriasis Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing elderly population worldwide
  • Increasing incidence of plaque psoriasis and psoriasis arthritis
  • Favorable reimbursement policies for such therapeutics
• Market Restraints
  • High cost of therapeutics
• Market Opportunities
  • Rising prescription volume and approvals of biologic products
  • Emerging development of new biologics and novel pipeline drugs
• Market Challenges
  • Probable health risks due to the medication

Porter's Five Forces: A Strategic Tool for Navigating the Psoriasis Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Psoriasis Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Psoriasis Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Psoriasis Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Psoriasis Therapeutics Market

A detailed market share analysis in the Psoriasis Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Psoriasis Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Psoriasis Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Psoriasis Therapeutics Market

A strategic analysis of the Psoriasis Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Psoriasis Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen, Inc., Astellas Pharma Inc., AstraZeneca Plc, Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Johnson & Johnson services, inc, LEO Pharma A/S, Merck & Co., Inc., Novartis AG, Pfizer Inc, and Sun Pharmaceutical Industries Limited.

Market Segmentation & Coverage

This research report categorizes the Psoriasis Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Molecule, market is studied across Biologics and Small Molecules.
• Based on Route of Administration, market is studied across Oral, Parenteral, and Topical.
• Based on Dosage Forms, market is studied across Liquid, Semi-Solid, and Solid.
• Based on Mechanism of Action, market is studied across IL Blocker, PDE4 Inhibitors, and TNF Inhibitors.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing elderly population worldwide
    • 5.1.1.2. Increasing incidence of plaque psoriasis and psoriasis arthritis
    • 5.1.1.3. Favorable reimbursement policies for such therapeutics
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of therapeutics
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising prescription volume and approvals of biologic products
    • 5.1.3.2. Emerging development of new biologics and novel pipeline drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Probable health risks due to the medication
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Psoriasis Therapeutics Market, by Molecule

• 6.1. Introduction
• 6.2. Biologics
• 6.3. Small Molecules

7. Psoriasis Therapeutics Market, by Route of Administration

• 7.1. Introduction
• 7.2. Oral
• 7.3. Parenteral
• 7.4. Topical

8. Psoriasis Therapeutics Market, by Dosage Forms

• 8.1. Introduction
• 8.2. Liquid
• 8.3. Semi-Solid
• 8.4. Solid

9. Psoriasis Therapeutics Market, by Mechanism of Action

• 9.1. Introduction
• 9.2. IL Blocker
• 9.3. PDE4 Inhibitors
• 9.4. TNF Inhibitors

10. Americas Psoriasis Therapeutics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Psoriasis Therapeutics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Psoriasis Therapeutics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Amgen, Inc.
• 3. Astellas Pharma Inc.
• 4. AstraZeneca Plc
• 5. Bausch Health Companies Inc.
• 6. Boehringer Ingelheim International GmbH
• 7. Eli Lilly and Company
• 8. F. Hoffmann-La Roche AG
• 9. GlaxoSmithKline plc
• 10. Johnson & Johnson services, inc
• 11. LEO Pharma A/S
• 12. Merck & Co., Inc.
• 13. Novartis AG
• 14. Pfizer Inc
• 15. Sun Pharmaceutical Industries Limited